Zacks Research Issues Pessimistic Forecast for PCRX Earnings

Pacira BioSciences, Inc. (NASDAQ:PCRX) – Stock analysts at Zacks Research dropped their FY2024 earnings per share (EPS) estimates for Pacira BioSciences in a note issued to investors on Tuesday, February 11th. Zacks Research analyst R. Department now forecasts that the company will post earnings of $2.61 per share for the year, down from their prior forecast of $2.63. The consensus estimate for Pacira BioSciences’ current full-year earnings is $2.40 per share. Zacks Research also issued estimates for Pacira BioSciences’ Q4 2024 earnings at $0.59 EPS, Q1 2025 earnings at $0.63 EPS, Q2 2025 earnings at $0.68 EPS, Q3 2025 earnings at $0.66 EPS, Q4 2025 earnings at $0.68 EPS, FY2025 earnings at $2.66 EPS, Q1 2026 earnings at $0.65 EPS, Q2 2026 earnings at $0.69 EPS, Q3 2026 earnings at $0.67 EPS and FY2026 earnings at $2.83 EPS.

Other research analysts have also recently issued research reports about the company. HC Wainwright reiterated a “buy” rating and issued a $39.00 target price on shares of Pacira BioSciences in a research report on Wednesday, December 4th. Truist Financial upgraded Pacira BioSciences from a “sell” rating to a “hold” rating and lifted their target price for the company from $8.00 to $25.00 in a research report on Thursday, January 30th. Needham & Company LLC boosted their price target on Pacira BioSciences from $22.00 to $30.00 and gave the stock a “buy” rating in a report on Monday, January 13th. Barclays reduced their price target on Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating on the stock in a report on Tuesday, November 12th. Finally, Royal Bank of Canada restated a “sector perform” rating and set a $18.00 price target on shares of Pacira BioSciences in a report on Tuesday, January 14th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $22.78.

Pacira BioSciences Stock Down 2.2 %

PCRX stock opened at $26.53 on Friday. Pacira BioSciences has a 52 week low of $11.16 and a 52 week high of $31.67. The company has a quick ratio of 1.89, a current ratio of 2.25 and a debt-to-equity ratio of 0.51. The business has a 50-day simple moving average of $21.72 and a 200 day simple moving average of $18.06. The company has a market cap of $1.22 billion, a PE ratio of -13.07 and a beta of 0.80.

Hedge Funds Weigh In On Pacira BioSciences

A number of institutional investors have recently modified their holdings of PCRX. Truist Financial Corp acquired a new position in shares of Pacira BioSciences during the second quarter worth approximately $423,000. SG Americas Securities LLC raised its position in shares of Pacira BioSciences by 96.4% during the third quarter. SG Americas Securities LLC now owns 25,254 shares of the company’s stock worth $380,000 after purchasing an additional 12,396 shares during the period. CWM LLC raised its position in shares of Pacira BioSciences by 713.6% during the third quarter. CWM LLC now owns 6,517 shares of the company’s stock worth $98,000 after purchasing an additional 5,716 shares during the period. Inspire Investing LLC raised its position in shares of Pacira BioSciences by 122.7% during the third quarter. Inspire Investing LLC now owns 27,474 shares of the company’s stock worth $413,000 after purchasing an additional 15,138 shares during the period. Finally, Wedge Capital Management L L P NC raised its position in shares of Pacira BioSciences by 131.9% during the third quarter. Wedge Capital Management L L P NC now owns 119,447 shares of the company’s stock worth $1,798,000 after purchasing an additional 67,947 shares during the period. 99.73% of the stock is owned by institutional investors and hedge funds.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.